Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.

Abstract

We examined the activities of peptidases in synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Dipeptidyl peptidase IV (DPP IV) activity was lower in synovial fluid from patients with RA, in contrast to the increase of DPP II activity in synovial fluid, as compared with OA. The DPP II/DPP IV ratio for synovial fluid was significantly higher in patients with RA than in patients with OA. A significant correlation was observed between the DPP II/DPP IV ratio for synovial fluid from patients with RA and the amount of C-reactive protein reaction. These results may be useful in the diagnosis of joint effusion of unknown origin.

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

“…Altered DPP4 activity was first noted in mice with RA in 1989 (Gotoh, Hagihara, Nagatsu, Iwata, & Miura, 1989). To gain insights into the pathophysiological role of CD26 in arthritis, Busso et al explored DPP4 expression in experimental mice model of arthritis, murine antigen-induced arthritis (AIA), and found a reduced plasma DPP4 activity in those mice models (Busso et al, 2005).…”

Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study

“…* Yi-Wen Tsai tsaiyiwen@gmail.com Extended author information available on the last page of the article autoimmune disease [7], inflammatory disease and malignancies [8]. Several groups have investigated altered DPP-4 activity in autoimmune disorders such as rheumatoid arthritis (RA) [4,[9][10][11][12][13], systemic lupus erythematosus (SLE) [14], psoriasis [15], inflammatory bowel disease (IBD) [16] and multiple sclerosis [17]. Many studies discovered decreased expression of both CD26 and levels of DPP-4 activity in subjects with RA, a systemic inflammatory disease involving joint destruction.…”

Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study

“…DPP‐4 is a ubiquitous protease with many substrates, and its function is not restricted to incretin regulation. In clinical settings, altered levels of DPP‐4 expression and DPP‐4 enzyme activity have been reported in several immune‐mediated diseases, including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), multiple sclerosis (MS) and systemic lupus erythematosus (SLE) . These results indicate that DPP‐4 mediates immune function and disease pathogenesis via the development, maturation and migration of T cells, cytokine secretion, T cell‐dependent antibody production, and immunoglobulin isotype switching of B cells .…”